Free Trial Information
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

ArcherDX picks deal with Invitae over IPO Genetic testing company Invitae (NYSE:NVTA) is acquiring ArcherDX Inc., adding a cancer diagnostics platform to its precision oncology business. ArcherDX’s shareholders will receive $325 million in cash plus...
Read More
BioCentury | Dec 26, 2019
Company News

Dec. 27 Company Quick Takes: Immunomedics, Qiagen, Eisai-Gilead, Melinta, Denovo-Rumpus

...plus royalties, according to Denovo investor Sangel Capital. Denovo has rights to the AKT and PRKCB...
...AKT1; PKB; PKBA) - Protein kinase B; EGP-1 - Epithelial glycoprotein-1; JAK-1 - Janus kinase-1; PRKCB...
...Inc. Eisai Co. Ltd. Gilead Sciences Inc. Denovo Biopharma LLC Melinta Therapeutics Inc. Protein kinase B (AKT) (AKT1) (PKB) (PKBA) Protein kinase C (PKC) beta (PRKCB) Rumpus...
Read More
BioCentury | Apr 1, 2019
Clinical News

Roche's ipatasertib-Tecentriq combo leads to 73% ORR in TNBC patients

Roche plans to start a Phase III trial this year to evaluate a combination of ipatasertib plus PD-L1 inhibitor Tecentriq atezolizumab and paclitaxel as first-line treatment of metastatic triple-negative breast cancer following a Phase Ib...
Read More
BioCentury | Jun 15, 2018
Company News

Denovo gains IP from Stanford to develop lead program for new indication

...The compound is a synthetic protein kinase B (AKT; AKT1; PKB; PKBA) and protein kinase C (PKC) beta (PRKCB...
Read More
BioCentury | Oct 27, 2017
Clinical News

U.S. and China clear Phase III of DB102 to treat DLBCL

...to previous clinical trials. The synthetic protein kinase B (AKT; AKT1; PKB; PKBA) and protein kinase C (PKC) beta (PRKCB...
...target: Protein kinase C (PKC) beta (PRKCB) ; Protein kinase B (AKT; AKT1; PKB; PKBA) Description: Synthetic AKT and PRKCB...
...start Milestone: NA Jennie Walters DB102 enzastaurin LY317615 Denovo Biopharma LLC Eli Lilly and Co. Protein kinase B (AKT) (AKT1) (PKB) (PKBA) Protein kinase C (PKC) beta (PRKCB...
Read More
BioCentury | Oct 17, 2017
Distillery Techniques

Chemistry

...two previously unreported bryostatin-1 analogs derived from intermediates in the 29-step reaction bound PKC β (PRKCB...
...13, 2017 doi:10.1126/science.aan7969 CONTACT: Paul A. Wender, Stanford University, Stanford, Calif. email: wenderp@stanford.edu Hongjiang Li Stanford University Protein kinase C (PKC) beta (PRKCB) Protein...
Read More
BioCentury | May 23, 2016
Clinical News

Ipatasertib: Phase II data

A double-blind, placebo-controlled, international Phase II trial in 253 patients with metastatic CRPC previously treated with docetaxel showed that once-daily 400 mg oral ipatasertib plus Zytiga abiraterone and prednisone non-significantly improved median radiographic PFS (8.2...
Read More
BioCentury | Jan 22, 2015
Distillery Techniques

Techniques: Epigenetic markers of susceptibility to type 2 diabetes

...hypermethylation of GPR61 (G protein-coupled receptor 61) and hypomethylation of PKCβ (protein kinase Cβ; PRKCB...
Read More
BioCentury | Nov 10, 2014
Company News

Eli Lilly, Denovo Biopharma deal

...of enzastaurin to treat DLBCL. Enzastaurin is a synthetic protein kinase B (PKB; Akt) and protein kinase C (PKC) beta...
Read More
BioCentury | Aug 28, 2014
Cover Story

Overcoming ibrutinib resistance

...a pathway that involves phospholipase Cg2 (phosphatidylinositol-specific) ( PLCG2 ) and protein kinase Cb ( PRKCB...
Read More
Items per page:
1 - 10 of 71